United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $511.09, for a total value of $4,855,355.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $165,819,572.87. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Price Performance

Shares of UTHR traded up $2.32 during trading hours on Tuesday, reaching $512.70. 456,329 shares of the company’s stock traded hands, compared to its average volume of 488,812. United Therapeutics Corporation has a twelve month low of $375.61 and a twelve month high of $609.35. The business’s fifty day simple moving average is $529.90 and its two-hundred day simple moving average is $539.42. The firm has a market capitalization of $21.99 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.41 earnings per share. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Bank of America decreased their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Institutional Trading of United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. California State Teachers Retirement System raised its position in shares of United Therapeutics by 55,526.2% during the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after purchasing an additional 33,229,108 shares during the period. BlackRock Inc. acquired a new position in shares of United Therapeutics in the second quarter worth about $2,868,735,000. Avoro Capital Advisors LLC increased its position in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.